- Home
- BCAT vs PRCT Comparison
BCAT vs PRCT Comparison
Compare BCAT & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BCAT | PRCT |
|---|---|---|
| Founded | 2020 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | BCAT | PRCT |
|---|---|---|
| Price | $14.62 | $27.13 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $35.44 |
| AVG Volume (30 Days) | 728.4K | ★ 2.1M |
| Earning Date | 01-01-0001 | 05-27-2026 |
| Dividend Yield | ★ 9.38% | N/A |
| EPS Growth | N/A | ★ 1.71 |
| EPS | ★ 1.43 | N/A |
| Revenue | N/A | ★ $308,054,000.00 |
| Revenue This Year | N/A | $32.85 |
| Revenue Next Year | N/A | $24.66 |
| P/E Ratio | $10.45 | ★ N/A |
| Revenue Growth | N/A | ★ 37.22 |
| 52 Week Low | $12.91 | $19.35 |
| 52 Week High | $15.41 | $64.89 |
Technical Indicators
Market Signals| Indicator | BCAT | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 37.01 | 50.70 |
| Support Level | $14.64 | $19.35 |
| Resistance Level | $14.84 | $29.24 |
| Average True Range (ATR) | 0.18 | 2.17 |
| MACD | -0.06 | 0.30 |
| Stochastic Oscillator | 0.65 | 86.18 |
Price Performance
Historical ComparisonAbout BCAT BlackRock Capital Allocation Term Trust of Beneficial Interest
BlackRock Capital Allocation Trust is a non-diversified, closed-end management investment company. The investment objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation.
About PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.